SI3393510T1 - Cepivo proti virusu ZIKA - Google Patents

Cepivo proti virusu ZIKA

Info

Publication number
SI3393510T1
SI3393510T1 SI201631676T SI201631676T SI3393510T1 SI 3393510 T1 SI3393510 T1 SI 3393510T1 SI 201631676 T SI201631676 T SI 201631676T SI 201631676 T SI201631676 T SI 201631676T SI 3393510 T1 SI3393510 T1 SI 3393510T1
Authority
SI
Slovenia
Prior art keywords
zika virus
virus vaccine
vaccine
zika
virus
Prior art date
Application number
SI201631676T
Other languages
English (en)
Inventor
Calzado Jana Barbero
Mario Nebenfuhr
Robert Schlegl
Michael Weber
Jurgen Wruss
Original Assignee
Valneva Austria Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57821924&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI3393510(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Valneva Austria Gmbh filed Critical Valneva Austria Gmbh
Publication of SI3393510T1 publication Critical patent/SI3393510T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • C07K14/1816—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus), border disease virus
    • C07K14/1825—Flaviviruses or Group B arboviruses, e.g. yellow fever virus, japanese encephalitis, tick-borne encephalitis, dengue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C12N7/06—Inactivation or attenuation by chemical treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • C12N2770/24163—Methods of inactivation or attenuation by chemical treatment
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SI201631676T 2015-12-23 2016-12-23 Cepivo proti virusu ZIKA SI3393510T1 (sl)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP15202585 2015-12-23
EP16161068 2016-03-18
EP16176049 2016-06-23
EP16176025 2016-06-23
EP16182845 2016-08-04
PCT/EP2016/082664 WO2017109225A1 (en) 2015-12-23 2016-12-23 Zika virus vaccine
EP16828746.4A EP3393510B1 (en) 2015-12-23 2016-12-23 Zika virus vaccine

Publications (1)

Publication Number Publication Date
SI3393510T1 true SI3393510T1 (sl) 2023-04-28

Family

ID=57821924

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201631676T SI3393510T1 (sl) 2015-12-23 2016-12-23 Cepivo proti virusu ZIKA

Country Status (19)

Country Link
US (13) US10660950B2 (sl)
EP (9) EP3393506B1 (sl)
JP (1) JP6949027B2 (sl)
KR (1) KR20180097558A (sl)
CN (2) CN115381934A (sl)
AU (1) AU2016375338B2 (sl)
BR (1) BR112018012873A2 (sl)
CA (1) CA3009278A1 (sl)
DK (1) DK3393510T5 (sl)
ES (4) ES2976311T3 (sl)
FI (1) FI3393510T3 (sl)
HR (1) HRP20230273T1 (sl)
HU (1) HUE061679T2 (sl)
LT (1) LT3393510T (sl)
MX (1) MX2018007627A (sl)
PL (1) PL3393510T3 (sl)
SG (1) SG11201805120YA (sl)
SI (1) SI3393510T1 (sl)
WO (6) WO2017109225A1 (sl)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9895437B2 (en) 2012-04-18 2018-02-20 Valneva Austria Gmbh Aluminum compounds for use in therapeutics and vaccines
CA3209607A1 (en) * 2015-07-16 2017-01-19 Bharat Biotech International Limited Vaccine compositions
WO2017109225A1 (en) 2015-12-23 2017-06-29 Valneva Austria Gmbh Zika virus vaccine
WO2018009604A1 (en) * 2016-07-08 2018-01-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric dengue/zika viruses live-attenuated zika virus vaccines
JP7301811B2 (ja) 2017-09-21 2023-07-03 ヴァルネヴァ エスイー 免疫原性チクングニアウイルスｃｈｉｋｖ－ｄｅｌｔａ ５ｎｓｐ３を含む医薬組成物を製造する方法
CN111511395B (zh) * 2017-11-03 2024-10-15 武田疫苗股份有限公司 用于将寨卡病毒灭活和用于确定灭活完全性的方法
CN107988239B (zh) * 2017-11-29 2021-03-19 南方医科大学 一种寨卡病毒的重组基因及其制备方法和应用
JP2021505549A (ja) * 2017-11-30 2021-02-18 タケダ ワクチン, インコーポレイテッドTakeda Vaccines, Inc. ジカワクチン及び免疫原性組成物、ならびにその使用方法
CN107904215B (zh) * 2017-12-27 2021-07-27 华农（肇庆）生物产业技术研究院有限公司 一种禽流感病毒的全悬浮培养方法
TWI658848B (zh) * 2018-02-13 2019-05-11 國立清華大學 茲卡病毒疫苗組合物及其應用
CN110156880B (zh) * 2018-02-13 2022-12-16 吴夙钦 兹卡病毒疫苗组合物及其应用
US11957746B2 (en) * 2018-03-26 2024-04-16 Boehringer Ingelheim Animal Health USA Inc. Method of producing an immunogenic composition
CN108676780B (zh) * 2018-07-24 2021-08-10 华中农业大学 一种高效分离猪肠道冠状病毒的方法
CN109337876A (zh) * 2018-10-15 2019-02-15 北京世纪元亨动物防疫技术有限公司 一种猪流行性腹泻病毒的纯化方法
JP7463366B2 (ja) 2018-11-20 2024-04-08 タケダ ワクチン，インコーポレイテッド 新規の抗ジカウイルス抗体及びその使用
CN109627297B (zh) * 2018-12-29 2022-06-14 复旦大学 来自寨卡病毒e蛋白的中和表位及其应用
WO2020154445A1 (en) * 2019-01-22 2020-07-30 Bluebird Bio, Inc. Methods and systems for manufacturing viral vectors
WO2020226831A1 (en) * 2019-05-08 2020-11-12 Takeda Vaccines, Inc. Inactivated virus compositions and zika vaccine formulations
AU2020328159A1 (en) 2019-08-09 2022-01-27 Valneva Se Single shot Chikungunya virus vaccine
CA3149919A1 (en) 2019-08-09 2021-02-18 Valneva Se Chikungunya vaccine formulations
EP4028511A1 (en) 2019-09-09 2022-07-20 Valneva Austria GmbH Inactivation process for viruses
KR102243295B1 (ko) * 2019-11-15 2021-04-23 강원대학교산학협력단 지카바이러스의 외피 단백질을 포함하는 재조합 백신 조성물
KR102365464B1 (ko) * 2019-12-24 2022-02-22 강원대학교산학협력단 지카바이러스 재조합 서브유닛 백신의 개발 및 이의 제조방법
WO2021158815A1 (en) * 2020-02-05 2021-08-12 New York Blood Center, Inc. Zika virus immunogenic compositions
WO2021176434A1 (en) 2020-03-01 2021-09-10 Valneva Austria Gmbh Cpg-adjuvanted sars-cov-2 virus vaccine
EP3895729A1 (en) 2020-03-01 2021-10-20 Valneva Austria GmbH Cpg-adjuvanted sars-cov-2 virus vaccine
US20240189412A1 (en) * 2020-03-03 2024-06-13 Mayo Foundation For Medical Education And Research Zika Virus Polypeptides
WO2021204825A2 (en) 2020-04-06 2021-10-14 Valneva Austria Gmbh INACTIVATED SARS-CoV-2 VIRUS VACCINE
JP2023526493A (ja) 2020-05-20 2023-06-21 タケダ ワクチン，インコーポレイテッド ジカウイルス特異的抗体の検出方法
WO2021236225A1 (en) 2020-05-20 2021-11-25 Takeda Vaccines, Inc. Method for detection of zika virus specific antibodies
US20230204567A1 (en) 2020-05-20 2023-06-29 Takeda Vaccines, Inc. Method for determining the potency of antigens
WO2023148256A1 (en) 2022-02-02 2023-08-10 Valneva Austria Gmbh Inactivated sars-cov-2 virus vaccine

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US86061A (en) * 1869-01-19 Improved horse-power
CN1142271C (zh) * 1997-08-28 2004-03-17 第一制糖株式会社 适应非洲绿猴肾细胞的减毒的日本脑炎病毒和其疫苗
ATE471983T1 (de) * 1998-09-02 2010-07-15 Us Gov Health & Human Serv Dengue viren, die in mosquitos nicht replizieren, zur verwendung als impfstoff
AU2001275191A1 (en) 2000-05-31 2001-12-11 Chiron Corporation Method for the purification of alphavirus replicon particles
WO2002074963A1 (en) * 2001-03-16 2002-09-26 The Government Of The United States Of America, As Represented By The Secretary, Department Of Healt Dengue viruses that are replication defective in mosquitos for use as vaccines
WO2002089840A1 (en) * 2001-05-10 2002-11-14 The Regents Of The University Of California Recombinant bicistronic flaviviruses and methods of use thereof
ES2562456T3 (es) 2003-03-24 2016-03-04 Valneva Austria Gmbh Uso de un adyuvante que induce una respuesta inmune Th1 para mejorar las respuestas inmunes
WO2008026225A2 (en) * 2006-09-01 2008-03-06 Bharat Biotech International Limited A vaccine for chikungunya virus infection
WO2009048633A2 (en) 2007-10-11 2009-04-16 The Board Of Regents Of The University Of Texas System Chimeric chikungunya virus and uses thereof
KR20100137006A (ko) * 2008-04-21 2010-12-29 티슈 리제너레이션 쎄라퓨틱스, 인코포레이티드 생물학적 또는 화학적 물질에 대한 예방 또는 치료를 위한 유전적으로 변형된 인간 탯줄 혈관주위 세포
EP2370455B1 (en) * 2008-11-26 2019-07-03 Government of the United States of America, as represented by the Secretary, Department of Health and Human Services Virus like particle compositions and methods of use
WO2010085358A2 (en) * 2009-01-23 2010-07-29 The Board Of Regents Of The University Of Texas System Flaviviruses expressing the prm, e, and ns1 proteins of other flaviviruses and uses thereof
US8765148B2 (en) 2010-02-19 2014-07-01 Valneva Austria Gmbh 1C31 nanoparticles
DK2788023T3 (en) 2011-12-06 2016-12-19 Valneva Austria Gmbh Aluminum compounds for use in therapeutics and vaccines
US9895437B2 (en) * 2012-04-18 2018-02-20 Valneva Austria Gmbh Aluminum compounds for use in therapeutics and vaccines
US10086061B2 (en) 2015-03-11 2018-10-02 The United States Of America, As Represented By The Secretary Of The Army, On Behalf Of The Walter Reed Army Institute Of Research Combination purified inactivated vaccine for flaviviruses
CA3209607A1 (en) * 2015-07-16 2017-01-19 Bharat Biotech International Limited Vaccine compositions
WO2017109225A1 (en) 2015-12-23 2017-06-29 Valneva Austria Gmbh Zika virus vaccine
CN105749268B (zh) 2016-04-11 2020-09-11 北京科兴中维生物技术有限公司 一种灭活的寨卡病毒疫苗
JP7301811B2 (ja) 2017-09-21 2023-07-03 ヴァルネヴァ エスイー 免疫原性チクングニアウイルスｃｈｉｋｖ－ｄｅｌｔａ ５ｎｓｐ３を含む医薬組成物を製造する方法

Also Published As

Publication number Publication date
US11207397B2 (en) 2021-12-28
EP3393508A1 (en) 2018-10-31
AU2016375338A1 (en) 2018-07-05
EP3393507B1 (en) 2024-02-07
AU2016375338B2 (en) 2021-11-04
BR112018012873A2 (pt) 2018-12-04
EP3393510B1 (en) 2023-02-22
ES2976311T3 (es) 2024-07-29
US20180362937A1 (en) 2018-12-20
US11951163B2 (en) 2024-04-09
WO2017109228A1 (en) 2017-06-29
HRP20230273T1 (hr) 2023-04-28
EP3393507A1 (en) 2018-10-31
EP4253403A3 (en) 2023-12-27
EP4357355A3 (en) 2024-09-25
EP3393507C0 (en) 2024-02-07
WO2017109224A1 (en) 2017-06-29
CN108697785B (zh) 2022-08-02
US11524064B2 (en) 2022-12-13
US20230226165A1 (en) 2023-07-20
FI3393510T3 (fi) 2023-03-22
JP6949027B2 (ja) 2021-10-20
WO2017109225A1 (en) 2017-06-29
EP4218807A2 (en) 2023-08-02
US10639365B2 (en) 2020-05-05
US10744194B2 (en) 2020-08-18
EP3393509A1 (en) 2018-10-31
DK3393510T3 (da) 2023-03-13
JP2019504030A (ja) 2019-02-14
MX2018007627A (es) 2019-02-14
US20200017555A9 (en) 2020-01-16
EP3393508B1 (en) 2023-06-07
EP4357355A2 (en) 2024-04-24
CA3009278A1 (en) 2017-06-29
EP3393506A1 (en) 2018-10-31
KR20180097558A (ko) 2018-08-31
PL3393510T3 (pl) 2023-06-26
EP4393938A2 (en) 2024-07-03
EP3393510A1 (en) 2018-10-31
US20180371027A1 (en) 2018-12-27
CN108697785A (zh) 2018-10-23
US20200197506A1 (en) 2020-06-25
CN115381934A (zh) 2022-11-25
US20200368342A1 (en) 2020-11-26
WO2017109227A1 (en) 2017-06-29
SG11201805120YA (en) 2018-07-30
US20200384099A1 (en) 2020-12-10
US10537630B2 (en) 2020-01-21
EP3393506C0 (en) 2024-03-13
EP3393509C0 (en) 2024-02-28
EP3393509B1 (en) 2024-02-28
US20240108712A1 (en) 2024-04-04
ES2973267T3 (es) 2024-06-19
US20230056142A1 (en) 2023-02-23
EP3393508B9 (en) 2023-09-27
US11406700B2 (en) 2022-08-09
US20190008945A1 (en) 2019-01-10
ES2950887T3 (es) 2023-10-16
US12005111B2 (en) 2024-06-11
LT3393510T (lt) 2023-03-27
US20180362936A1 (en) 2018-12-20
EP3393508C0 (en) 2023-06-07
US20210093707A1 (en) 2021-04-01
EP4218807A3 (en) 2023-09-06
US10660950B2 (en) 2020-05-26
ES2941967T3 (es) 2023-05-29
US20180369359A1 (en) 2018-12-27
WO2017109229A1 (en) 2017-06-29
DK3393510T5 (da) 2024-09-30
WO2017109223A1 (en) 2017-06-29
HUE061679T2 (hu) 2023-08-28
US11331382B2 (en) 2022-05-17
EP4393938A3 (en) 2024-08-07
EP3393506B1 (en) 2024-03-13
US20220273786A1 (en) 2022-09-01
EP4253403A2 (en) 2023-10-04
US11219681B2 (en) 2022-01-11
US12102673B2 (en) 2024-10-01

Similar Documents

Publication Publication Date Title
PL3393510T3 (pl) Szczepionka przeciwko wirusowi zika
SG10201913630YA (en) Zika virus vaccine
ZA201804071B (en) Recombinant zika vaccines
IL258831A (en) Assemble respiratory syncytial virus
SI3718565T1 (sl) Cepiva za respiratorni virus
HK1246183A1 (zh) Hpv疫苗
LT3371316T (lt) Vakcinos nuo hepatito b viruso
ZA201700165B (en) Influenza virus vaccines and uses thereof
GB201613191D0 (en) Zika virus vaccine
GB201518684D0 (en) Vaccine
GB201406608D0 (en) Virus
SG11201610443WA (en) Influenza virus vaccines and uses thereof
GB201522132D0 (en) Vaccine
GB201419572D0 (en) Virus
GB201506041D0 (en) Avian vaccine
PT3393510T (pt) Vacina contra o vírus zika
IL249705A0 (en) Influenza virus vaccines and their uses
IL249704A0 (en) Influenza virus vaccines and their uses
GB201522013D0 (en) Virus
GB201516936D0 (en) Virus
GB201507419D0 (en) Virus
GB201507529D0 (en) Virus preparations
GB201406470D0 (en) Virus
GB201408046D0 (en) Virus preparations
GB201403582D0 (en) Virus